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Are there candidates for high-dose chemotherapy
in ovarian carcinoma?
Renaud Sabatier1,2*, Anthony Gonçalves1,3,4, François Bertucci1,2,4, Maria-Antonietta Capiello1, Frédérique Rousseau1,
Eric Lambaudie5, Christian Chabannon4,6, Patrice Viens1,4 and Jean-Marc Extra1
Abstract
Background: Prognosis of advanced ovarian carcinomas (AOC) remains poor with a 5-year survival of 30%. Benefit
from high-dose chemotherapy (HDC) in this disease has not been demonstrated to date.
Methods: To evaluate the value of HDC as consolidation treatment after surgery and platinum/taxane-based
therapy, we designed a monocentric retrospective comparative study. We used a subset approach to identify
parameters associated with HDC efficacy.
Results: One hundred and three AOC patients treated with conventional chemotherapy alone (CCA) were
compared to 60 patients receiving HDC plus hematopoietic stem cell support. After a median follow-up of 47.5
months there was no overall survival (OS) advantage for the HDC group in the whole population (p=0.29).
Nevertheless, HDC was associated to a better outcome in young patients (≤50 years), both in term of
progression-free survival (p=0.02, log-rank test) and OS (p=0.05, log-rank test). Median OS was 54.6 and 36 months
in the HDC and CCA groups, respectively.
Conclusions: Although randomized trials failed to demonstrate any benefit for HDC in AOC patients, this study
suggests that young patients may derive a substantial advantage from receiving it after the standard treatment.
Further prospective studies are warranted to confirm this gain and to search for the biological processes associated
with this improvement.
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Background
Ovarian carcinoma is the first cause of death by gyneco-
logic malignancy in western countries. In 2010 in USA,
around 22 000 cases were diagnosed and 14 000 deaths
were reported [1]. Such a poor prognosis is due to late
diagnosis and relative lack of efficacy of current treat-
ments. The therapeutic sequence used by most of clini-
cians is maximal cytoreductive surgery (also called
debulking surgery) followed by adjuvant chemotherapy
for undifferentiated or advanced tumors [2-7]. Neverthe-
less, 20% of patients are initially refractory to this treat-
ment and more than 50% of patients who are initially in
complete remission will relapse and ultimately succumb
from disease [8,9]. Consequently, overall survival is quite
reduced and has remained stable since 20 years (30-40%
at five years for all stages). Early stages have a favorable
prognosis (~90%), while life expectancy is only 30% after
5 years when disease is extended to peritoneal cavity and
only 5-10% when there is distant metastasis [8,9].
A combination of a platinum agent and paclitaxel is
the standard therapy with benefits in terms of response,
progression-free and overall survivals, leading in stages
III and IV to a median survival of more than 35 months
[10,11]. Several laboratory models [12] as well as retro-
spective analyses of clinical studies [13,14] have strongly
suggested that chemotherapy dose could favorably influ-
ence ovarian cancer outcome. Major chemotherapy dose
intensification using alkylating agents with autologous
hematopoietic stem cell support (HSCS) has been inves-
tigated in this setting, with encouraging results in pilot
studies [15-18]. However, these promising results have
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not been confirmed in randomized phase III trials
[19,20], and high-dose chemotherapy (HDC) is currently
not recommended for advanced ovarian carcinomas
(AOC).
Nevertheless, ovarian cancer is clinically heteroge-
neous. Patients with morphologically similar, advanced-
stage tumors display a broad range of clinical outcomes.
Features currently used for prognosis and chemotherapy
decision are clinicopathological and include patient’s
age, performance status, FIGO stage, histological tumor
grade and subtype, initial surgery results and response to
chemotherapy. These factors were not incorporated in
the initial design of randomized studies although they
might be associated with different responses to HDC.
The present study is a retrospective comparative survi-
val analysis, including subsets analysis based on usual
clinicopathological features. A survival comparison was
done between 103 patients with AOC treated by surgery
plus platinum/taxane-based conventional chemotherapy
alone (CCA) and 60 patients who received the same
treatment plus HDC and autologous HSCS.
Methods
Population description
Patients were selected in our institutional “Ovarian Can-
cer” database, which included all ovarian cancer patients
treated at the Institut Paoli-Calmettes (Marseilles,
France) since 1995. Eligible patients were aged between
18 and 64 years and had histologically proven invasive
ovarian carcinoma with advanced (FIGO stage IIIc) or
metastatic (FIGO stage IV) disease at diagnosis.
All patients were treated using a standard multimodal
approach including surgery and platinum/taxane-based
chemotherapy. In the “HDC” group, patients also
received HDC with HSCS. Hematological rescue con-
sisted of autologous hematopoietic stem cells collected
from peripheral blood.
After completion of treatment, patients were evaluated
at 3-month intervals for the first 2 years and at 6-month
intervals thereafter. Evaluations included clinical exami-
nation and blood tests with CA125 assessment. CT scan
evaluations were performed every 6 months for the first
5 years and yearly thereafter. Other examinations were
performed only when indicated.
The study was approved by our institutional review
board. According to the French law, since it was a retro-
spective study without biological research and without
therapy modification, no personal consent was required.
Statistical analysis
Differences in patient characteristics between the two che-
motherapy groups (with vs. without HDC) were tested by
the Fisher’s exact test (categorical variables) or the Student’s
t-test (continuous variables). Tested parameters were age at
diagnosis (with a threshold at 50 years old), performance
status, FIGO stage, histological subtype (serous vs. others),
histological grade according to Silverberg classification
(grade 1 and 2 were pooled), presence of residual disease
after surgery, presence of a clinical remission after plati-
num/taxane-based therapy (according to clinical and radi-
ological examinations), CA125 normalization after
platinum/taxane-based therapy.
Progression-free survival (PFS) was calculated from
the date of diagnosis until date of first disease progres-
sion. Overall survival (OS) was calculated from the date
of diagnosis until date of death of any cause. Follow-up
was measured from the date of diagnosis to the date of
last news for live patients. Data concerning patients
without disease progression or death at last follow-up
were censored. Survival curves were estimated using the
Kaplan-Meier method, and compared with the log-rank
test. The prognostic impact of above-cited factors and
chemotherapy regimen was assessed by the Cox regres-
sion method both in univariate and multivariate analysis.
Multivariate analyses only included variables with p-
value lower than 5% in univariate analysis. All statistical
tests were two-sided at the 5% level of significance. Sta-
tistical analyses were performed using SPSS software
(version 16.0).
Results
Patients and treatment
One hundred sixty-three patients with advanced ovarian
carcinomas treated at our institution between April 1995
and July 2009 were included in this study. Tumor char-
acteristics are listed in Table 1. Median age at diagnosis
was 54 years (standard deviation, 8.7 years) and 68%
were older than 50 years. Fifty three percent were grade
II serous tumors. Complete cytoreductive surgery could
not be achieved for 41% of patients. Seventy percent pre-
sented no clinical residual disease after conventional
treatment including surgery and chemotherapy. All
patients received a platinum/taxane-based chemother-
apy. Ninety percent of patients received carboplatin, 10%
cisplatin, 79% paclitaxel and 21% docetaxel. Carboplatin
was given every three weeks, according to the Calvert’s
formula with an area under curve of 6 before and 5 after
January 2005. Cisplatin was given every three weeks at a
dose of 75 mg/m2. Paclitaxel was administered every
three weeks at the dose of 175 mg/m2 until 2008, and
then weekly at the dose of 80 mg/m2. Docetaxel was
given with a 3-weeks frequency, at the dose of 75 mg/m2.
Patients received a median of 6 cycles, with a minimum of
1, and a maximum of 8 cycles.
Seventy-one patients underwent second look surgery
after platinum/taxane-based chemotherapy. Of them, 25
presented a pathological complete response. Eighteen
percent did not reach CA125 normalization after
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standard treatment achievement. Median PFS of the
whole population was 18.8 months, with a 5-year PFS of
25.4%. Median OS was 42.7 months, with a 5-year OS of
32.6% (Figure 1).
Out of these 163 patients, two groups were distin-
guished with respect to the regimen of chemotherapy:
103 patients (63%) received conventional chemotherapy
alone (“CCA group”) and 60 patients (37%) received
HDC with HSCS after completion of a platinum/
taxane-based regimen (“HDC group”). Median time
from platinum/taxane-based chemotherapy completion
to HDC was 2.8 months. Because of the large period of
inclusion, HDC regimens were heterogeneous. Never-
theless, all patients received alkylating agents. The
details of the HDC regimen are noted in Table 2. Med-
ian and mean numbers of re-injected hematopoietic
stem cells (CD34 positive cells) per patient were 6.1 mil-
lion and 8.3 million per Kg, respectively.
There was no statistically significant difference
between the two subsets (Table 1), except for clinical
complete remission after platinum/taxane-based regi-
men: 62% in the CCA group versus 83% in the HDC
Table 1 Clinicopathological features of advanced ovarian carcinomas with and without high-dose chemotherapy
CCA HDC p -value Odd or Hazard Ratio (95CI)
N N (%) N (%)
103 60
Follow-up (median, months) 163 46.7 48.2 0.08***
Median Age (years) 163 56,0 53,0 0 09***
Age 163 0.73**** 1.15 [0.55-2.45]
≤50y 34 (33) 18 (30)
>50y 69 (67) 42 (70)
OMS 117 0.17**** 0.35 [0.06-1.37]
0-1 63 (81) 36 (92)
2-3 15 (19) 3 (8)
FIGO 163 0.33**** 1.47 [0.63-3.39]
IIIc 84 (82) 45 (75)
IV 19 (18) 15 (25)
Histological subtype 163 0.62**** 0.82 [0.40-1.65]
Serous 62 (60) 39 (65)
Others 41 (40) 21 (35)
Grade 98 0.01**** 0.32 [0.12-0.81]
1-2 19 (31) 21 (58)
3 43 (69) 15 (42)
Cytoreductive surgery 160
Complete 56 (56) 40 (67) 0.24**** 0.64 [0.31-1.30]
residual disease 44 (44) 20 (33)
Clinical complete response* 161
Yes 63 (62) 50 (83) 0.007**** 0.33 [0.14-0.77]
No 38 (38) 10 (17)
CA-125** 149 0.66**** 0.75 [0.27-1.92]
Normal 73 (80) 49 (85)
>Normal 18 (20) 9 (15)
Time from end of initial CT to
HDCT (median, months)
61 NA 2.8 NA NA
Median PFS (months) 18.1 20.1 0.09*****
Median OS (months) 41.3 47.3 0.24*****
CCA, conventional chemotherapy alone; HDC, high-dose chemotherapy; N, number of cases with data available; 95CI, 95% confidence interval; OMS, performance
status; NA, not asssessable; PFS, progression-free survival; OS, overall survival. *Clinical and radiological complete response after platinum and taxane-based
chemotherapy; **, CA-125 rate after platinum and taxane-based chemotherapy; ***, T-test; ****, Fisher's exact test; *****, Log-rank test.
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group (p=7.0 E-03, Fisher’s exact test). Such an imbal-
ance can be explained by the fact that only patients with
complete or at least partial response were candidate to
HDC. It is of note that no toxic death was observed in
the HDC arm.
Pathological response
Seventy-one patients underwent second look surgery
(SLS) at the end of the platinum/taxane-based treat-
ment. Among them, 27 received HDC after SLS. There
was no statistical difference in pathological response
between the HDC and the CCA subsets: seven patholo-
gical complete responses were observed in the HDC
subset (26%) and eighteen in the CCA group (41%),
p=0.31 (Fisher’s exact test).
Outcome and survival
Median follow-up was 47.5 months. There were 79 disease
progressions and 64 deaths in the conventional therapy
group versus 40 and 35, respectively in the HDC group.
Outcome evaluation according to therapy showed that
median PFS and OS were similar with 20.1 and 47.3
months in the HDC group versus 18.1 and 41.3 months in
the CCA group, respectively.
Prognostic parameters
In the whole population (Table 3A), PFS was influenced
by debulking surgery results (hazard ratio (HR) for pro-
gression of 0.38 if no residual disease was present),
response to therapy (HR=0.33 in case of complete clinical
response (CCR)), and CA125 normalization (HR=0.45).
Outcome was not significantly improved when HDC was
added (PFS, p=0.09; OS, p=0.24), (Figure 2). Multivariate
analysis showed that only two features had an independent
prognostic value in the whole population: surgical results
and clinical response to initial chemotherapy.
We then explored the prognostic value of the usual
clinicopathological features in each treatment arm.
We first examined PFS. In the CCA group, PFS was
influenced by debulking surgery results (HR=0.29), clin-
ical response to therapy (HR=0.32), and CA125 normal-
ization (HR=0.32). In the HDC arm, age (HR=2.07 if
older than 50 years) FIGO stage (HR=0.41 for stage IIIc)
and clinical response to initial treatment (HR=0.46) had
a prognostic value (Table 3B). When focusing only in
the pre-treatment clinicopathological features, only age
and FIGO stage had a prognostic value in the HDC
group.
Impact of HDC on PFS according to these last two
features was analyzed. HDC significantly improved PFS
in young patients (p=0.02, log-rank test), but had no
prognostic value in women older than 50 years (p=0.81,
log-rank test), (Figure 3). In the same way, HDC
increased PFS in stage IIIc patients (p=0.03, log-rank
test), but not in stage IV cases (p=0.94, log-rank test).
Cox regression analyses performed in both young
patients and stage IIIc cases found that PFS was signif-
icantly affected by HDC, surgical results, complete
remission and Ca125 normalization after conventional
treatment. Young patients had a 2.44-fold rate of pro-
gression if they did not receive HDC (Table 4); and stage
IIIc patients a 1.61-fold rate of progression if they did
not receive HDC (Additional file 1: Table S1). By multi-
variate analyses HDC had an independent prognostic
value in young patients (Table 4), but not in stage IIIc
cases (Additional file 1: Table S1).
We then explored the impact of chemotherapy regi-
men on OS according to the two factors independently
associated with a PFS improvement induced by HDC
(young age and FIGO stage IIIc). We could observe that
5-y PFS=25.4%
5-y OS=31.7%
Months after diagnosis
Figure 1 Survival curves of the whole population (n=163).
Progression-free survival in black (median PFS = 18.8 months), and
Overall survival in grey (median OS = 42.7 months), + censored data.
Table 2 High dose chemotherapy regimen in the
high-dose chemotherapy group (N=60)
N (%)
Carboplatin AUC 18 12 (20)
Cyclophosphamide 60mg/kg/d (d-3 to d-2) +
melphalan 140 mg/m2 d-1
32 (53)
Cycle 1: cyclophosphamide 60mg/kg/d (d-3 to d-2) +
melphalan 140 mg/m² d-1 +
Cycle 2: thiotepa 300mg/m²/d d-3 to d-2 8 (13)
Melphalan 140 mg/m² d-1 3 (5)
Thiotepa 300mg/m²/d d-3 to d-2 1 (2)
Cycle 1: melphalan 140 mg/m² d-1 +
Cycle 2: thiotepa 300mg/m²/d d-3 to d-2
2 (3)
Topotecan 7,5mg/m²/d (d-6 to d-2) 2 (3)*
N, number of patients; AUC, area under curve; d, day; *, patients treated in the
ITOV 01 trial.
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HDC plus HSCS significantly improved survival only
when age was under 50 years, but not in stage IIIc
patients (Figure 4). Median overall survival was highly
increased in young patients treated with HDC (54.6
months) when compared to conventional therapy alone
(36 months), (p=0.05). Effect of HDC according to FIGO
stage IIIc was less important and non significant: median
OS was 53.9 months in the HDC subset versus 41.3
months in the CCA subset (p=0.11).
It is worth to note that the prognostic value of HDC
was not modified by the initial response to treatment.
HDC improved survival in young patients whatever the
response to initial therapy was: median PFS was 5
months for CCA vs. 15 months for HDC in patients with
residual disease after treatment; and 38 months for CCA
whereas it had not been reached after a follow-up of 47
months in the HDC group for cases with initial CCR
and CA-125 normalization.
Discussion
Even though HDC plus HSCS cannot be considered as a
standard of care for all AOC patients, results from this
monocentric comparative retrospective study including
163 patients suggest that it may be beneficial to young
patients. In women under 50 years of age, addition of
HDC to platinum/taxane-based chemotherapy improves
not only PFS (p=0.02), but also OS (median of 54.6
months versus 36 months with conventional therapy
alone, p=0.05).
Despite advances in chemotherapy and multidisciplin-
ary management of ovarian carcinomas, the prognosis of
patients with advanced stages (FIGO III/IV) remains
poor. Median PFS and OS of our cohort treated with a
platinum/taxane combination alone (18.1 and 41.3
months, respectively) were similar to those of phase III
pivotal studies: 18 and 38 months [10], and 19.4 and
48.7 months [6] with cisplatin and paclitaxel; 20.7 and
Table 3 Prognostic parameters (PFS), Cox regression analysis
A. Whole population
Univariate analysis Multivariate analysis
N HR 95CI p -value N HR 95CI p -value
Age (>50y vs ≤50y) 163 1.12 0.76-1.66 0.57
OMS (0-1 vs 2-3) 117 1.53 0.88-2.67 0.14
FIGO (IIIc vs IV) 163 0.7 0.45-1.08 0.1
Histology (serous vs others) 163 0.95 0.66-1.39 0.8
Grade (1-2 vs 3) 98 1.2 0.93-1.55 0.16
Serous grade 3 (vs others) 98 1.42 0.80-2.52 0.23
Surgery (complete vs non complete) 160 0.38 0.26-0.54 2.23 E-07 147 0.57 0.37-0.87 0.01
Complete clinical remission (Yes vs No) 161 0.33 0.23-0.49 2.14 E-08 147 0.55 0.33-0.92 0.02
CA-125 (normal vs >normal) 149 0.45 0.29-0.71 6.9 E-04 147 0.77 0.45-1.32 0.34
Time from end of initial CT to HDC NA
Treatment (CCA vs HDC) 163 1.39 0.95-2.03 0.09
B. According to chemotheraphy regimen, univariate analysis
Conventional CT High dose CT
N HR 95CI p -value N HR 95CI p -value
Age (>50y vs ≤50y) 103 0.83 0.52-1.33 0.44 60 2.03 0.96-4.29 0.06
OMS (0-1 vs 2-3) 78 1.56 0.84-2.89 0.16 39 0.96 0.22-4.17 0.95
FIGO (IIIc vs IV) 103 0.93 0.52-1.70 0.82 60 0.4 0.20-0.78 0.007
Histology (serous vs others) 103 1.24 0.78-1.97 0.37 60 0.83 0.44-1.58 0.56
Grade (1-2 vs 3) 62 1.17 0.85-1.61 0.35 36 1.08 0.67-1.72 0.76
Serous grade 3 (vs others) 62 0.81 0.57-1.15 0.24 36 0.98 0.51-1.87 0.94
Surgery (complete vs non complete) 100 0.29 0.18-0.46 2.2 E-07 60 0.65 0.34-1.22 0.18
Complete clinical remission (Yes vs No) 101 0.32 0.20-0.51 1.78 E-06 60 0.44 0.20-0.97 0.04
CA-125 (normal vs >normal) 91 0.32 0.18-0.56 6.41 E-05 58 1.21 0.53 2.74
Time from end of initial CT to HDC NA 60 0.97 0.86-1.09 0.59
Treatment (CCA vs HDC) NA NA
PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; HDC, high-dose
chemotherapy; CCA, conventional chemotherapy alone.
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57.4 months for carboplatin and paclitaxel [6]. Our
population was thus similar to previously described
cohorts. Prognosis is known to be dramatically influ-
enced by cytoreductive surgery and response to adju-
vant platinum/taxane-based chemotherapy. However,
even good responders to initial treatment often have a
poor prognosis due to secondary relapse. Such relapses
are generally chemoresistant and remain the major
cause of death. Thus, it may be useful to treat chemo-
sensitive patients in order to kill residual clones and
avoid the chemoresistant relapse. Different consolida-
tion therapies have been considered: conventional main-
tenance chemotherapy, intraperitoneal treatment with
chemotherapy and/or hyperthermia, and HDC with
HSCS. The latter has been widely used in the context of
poor risk hematological malignancies and sometimes in
chemosensitive solid tumors such as metastatic breast
cancer [21-25] or germ cell tumors [26] with controver-
sial results.
The main toxicity of high-dose alkylating agents is
hematological. Stem cell transplantation is needed in
such treatment strategies to limit the duration and con-
sequences of aplasia. Nevertheless, severe infection can
always occur during grade 4 neutropenia and remains
the major potential risk during severe aplasia. However
we observed no toxic death after HDC in this study.
Several promising but preliminary studies have
reported that HDS plus HSCS may improve ovarian can-
cer outcome in first-line therapy. These results were
observed when HDC was used either as front-line treat-
ment [19,27], or as consolidation therapy [17,28-32].
However published randomized phase III trials did not
confirm these results. In a single center small-sized
study from Papadimitriou et al. [19], although PFS was
5-y PFS: 32.2% vs 21.9%
p=0.09, log-rank
Months after diagnosis
Pr
o
gr
es
si
on
-fr
ee
 s
u
rv
iv
al
O
v
er
al
l s
ur
vi
va
l
Months after diagnosis
5-y OS: 38.8% vs 29.3%
p=0.24, log-rank
A B
HDC
CCA
HDC
CCA
Figure 2 Progression-Free Survival (A) and Overall Survival (B) according to chemotherapy regimen in the whole population.
Conventional chemotherapy alone (CCA) alone in black, n=103; conventional chemotherapy plus high-dose chemotherapy in grey,
n=60, + censored data.
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Figure 3 Progression-Free Survival according to chemotherapy regimen. Conventional chemotherapy alone (CCA) in black or plus high-
dose chemotherapy (HDC) in grey. (A) In patients under 50 years of age (n=52), median PFS was 11 months in the CCA subset versus 81.7
months in the HDC subset. (B) In patients older than 50 years old (n=111), median PFS was 18.3 months in the CCA subset versus 17.9 months in
the HDC subset. + censored data.
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numerically improved by HDC (85.2 months versus 18
months), the difference was not significant (p=0.059).
Moreover, no significant difference was observed in OS
(not reached after 75 months of follow-up versus 75
months, p=0.38). The authors attributed PFS gain to the
higher rates of stages IV (14% vs. 8.1%) and larger post-
operative residue (32.6% vs. 21.6%) in the conventional
therapy arm. Mobus et al. reported similar findings in
their relatively large phase III trial published in 2007
[20]. Median PFS was 29.5 months in the HDC arm ver-
sus 20.5 in the control arm (p=0.40). There was also no
difference regarding OS (54.4 vs. 62.8 months, p=0.54).
Conclusions of these studies were that HDC does not
improve outcome in advanced ovarian cancer.
Nevertheless a question that could be asked is: are
these conclusions relevant for all patients or is there a
subset of patients who may benefit from HDC? In this
retrospective study, we tried to address this issue using a
subgroup analysis approach in a large population of
more than 160 patients. We have explored prognostic
value of the different histoclinical features used in
ovarian cancer evaluation: age, performance status,
FIGO stage, histological subtype, histological grade,
debulking status and response to conventional che-
motherapy. Age was the only parameter correlated to
HDC efficacy, both in PFS and OS. Intriguingly, patients
under 50 years of age had a gain in survival when HDC
was performed after platinum/taxane-based chemother-
apy: median OS of 54.6 months vs. 36 months with stan-
dard treatment (p=0.05). This benefit was observed
independently of the response after standard treatment.
A possible hypothesis is that, in young patients known
to have a better prognosis than older women, HDC may
be more efficient regardless of the persistence of residual
disease after conventional therapy. A hypothesis to
explain these results could be the higher prevalence of
BRCA-related tumors in younger patients compared to
sporadic forms [33,34]. Indeed, BRCA-related ovarian
cancers display distinctive biological and clinical charac-
teristics including genomic instability, dysfunction in
DNA repair processes especially homologous recombi-
nation and thereby higher sensitivity to platinum-based
Table 4 Prognostic features (PFS) in young patients (≤50 years), Cox regression analyses
Univariate analysis Multivariate analysis
N HR 95CI p-value N HR 95CI p-value
OMS (0-1 vs 2-3) 36 1.76 0.71-4.38 0.22
FIGO (IIIc vs IV) 52 0.57 0.25-1.33 0.19
Histology (serous vs others) 52 0.81 0.51-1.56 0.52
Grade (1-2 vs 3) 31 1.31 0.83-2.08 0.25
Serous grade 3 (vs others) 31 1.06 0.59-1.88 0.85
Surgery (complete vs non complete) 52 0.29 0.15-.058 4.97 E-07 51 0.43 0.19-0.94 0.034
Complete clinical remission (Yes vs No) 51 0.22 0.11-0.45 3.65 E-05 51 0.33 0.15-0.74 0.007
CA-125 (normal vs >normal) 44 1.87 0.84-4.16 0.12
Treatment (CCA vs HDC) 52 2.44 1.14-5.25 0.02 51 2.31 1.06-5.04 0.036
PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; CCA, conventional
chemotherapy alone; HDC, high-dose chemotherapy.
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Figure 4 Overall survival after conventional chemotherapy alone (black) or plus high dose chemotherapy (grey). (A) In patients under 50
years of age (n=52) median OS was 36 months in the CCA subset versus 54.6 months in the HDC subset; (B) in stage IIIc cases (n=129) median
OS was 42 months in the CCA subset versus 49.5 months in the HDC subset; + censored data.
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chemotherapy and better outcome [35,36]. Of note,
recent data have shown that this phenotype could be
extended to a larger group of tumors without germline
BRCA mutations, the so-called “BRCAness” phenotype
[37,38]. Thus, the benefit of alkylating agents-based
HDC in younger patients observed in this study may
reflect the enrichment in BRCA-related or BRCAness-
associated forms in this subgroup and therefore a higher
sensitivity of ovarian cancer cells to DNA damages that
can be induced by alkylating agents. As suggested by the
dose-effect concept, more chemotherapy –and thus
more DNA lesions- may lead to an increase in tumor
cells death.
A similar exploitation of this Achilles’ heel of the
BRCAness-related phenotype was recently demonstrated
with the new therapeutic class of PARP1 inhibitors [39],
which also target DNA repair processes. PARP1 inhibi-
tors are able to induce DNA single-strand breaks that
will accumulate and degenerate to DNA double-strand
breaks, which are not appropriately repaired if the BRCA
pathway is deficient or dysfunctional, the so-called syn-
thetic lethality concept. Olaparib has been shown to
induce relevant and promising rates of response when
used as single agent in AOC. Interestingly, its activity
was documented not only in patients carrying BRCA
mutations [40,41], but also in patients without constitu-
tive mutations [42], further validating the BRCAness
concept.
This phenomenon may be increased with the associa-
tion of PARP inhibitor and alkylating drugs. Such an
additive activity may not be necessary in case of com-
plete remission after standard treatment, but may have a
positive effect when the tumor burden has been
decreased but not eliminated by the initial treatment.
Our observations show that more treatment may be
more effective in young patients. Addition of HDC after
platinum/taxane-based chemotherapy in this population
should be compared to other ways to enhance treatment
exposure. Intra-peritoneal chemotherapy may be an
option to increase the doses of platinum and/or taxane
administered to cancer cells, with less hematological
adverse events [43]. Another issue is the lack of studies
comparing consolidation (such as HDC) and maintenance
therapy, which could be based on cytotoxic treatments
[44] as well as angiogenesis inhibitors [45]. Nevertheless
it is of note that, except angiogenesis inhibiting agents,
none of the treatments cited above has shown his super-
iority in randomized trials versus observation alone, but
without age consideration as we have done in this analy-
sis. These new findings must be balanced with the fact
that this study was retrospective, and that HDC regimens
were heterogeneous. Nevertheless, despite its retrospec-
tive nature, this study, based on a large population, used
a comparative design and included subgroup analyses
with traditional clinical and pathological prognostic fac-
tors. Another limitation of this work is the absence of
relevant information about the BRCA status of our
patients. Unfortunately, this data was available only for
few patients in our retrospective cohort (21 of 163), with
only six BRCA1 and two BRCA2 mutations identified.
Conclusions
We have shown in this retrospective comparative study
including more than 160 women, that, when applied to
all patients, HDC does not improve advanced ovarian
cancer survival. However, HDC seems to benefit to young
patients (less than 50 years of age). Median overall survi-
val in this subset presented an improvement of 18
months when HDC was performed after initial platinum/
taxane-based chemotherapy versus standard chemother-
apy alone. This work is the first to make the hypothesis
of a differential benefit from HDC according to age. As
we know that young patients have a higher frequency of
BRCA alterations than older women, they may have a
more important benefit from HDC. That may lead to
new clinical trials to explore this hypothesis of HDC use-
fulness in young patients, without or with combination
with drugs targeting DNA repair such as olaparib.
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